Possible role of epidermal growth factor receptors in the therapy of pancreatic cancer

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 28, Issue 4, 2011, Pages 293-356

  Aggarwal, Sahil ^a   Gupta, Swati ^a   Gupta, Manish K ^a   Murthy, R S R ^a   Vyas, Suresh P ^b  

^a ISF COLLEGE OF PHARMACY   (India)

^b DR H S GOUR UNIVERSITY   (India)

Author keywords

Active targeting; Endocytosis; Epidermal growth factor receptor; Pancreatic cancer; Passive targeting; Receptor signaling

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN; NOTCH4 RECEPTOR; OXALIPLATIN; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 6; PROTEIN P100; PROTEIN P16; PROTEIN P21; PROTEIN P53; SMAD4 PROTEIN; STAT PROTEIN; STEROID RECEPTOR COACTIVATOR 1; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG;

ANEMIA; APPETITE DISORDER; ARTICLE; BLADDER CANCER; BLEEDING; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; DIARRHEA; DNA DETERMINATION; ESOPHAGUS CANCER; FATIGUE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HAND PARESTHESIA; HUMAN; IN VITRO SELECTION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; MOUTH PAIN; NAUSEA AND VOMITING; ONCOGENE RAS; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PARESTHESIA; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBMANDIBULAR GLAND; TUMOR SUPPRESSOR GENE;

EID: 79961194239     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i4.10     Document Type: Article

References (314)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.
2. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197-209.
3. Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol. 2007;224:326-36.
4. Pliarchopoulou K, Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev. 2009;35:431-6.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
6. American Cancer Society, Facts and Figures 2010.
7. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanism involved in pancreatic cancer progression and therapies. Pancreas. 2005;31:301-16.
8. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1998;53:549-54.
9. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3:565-76.
10. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006a;66:2778-84.
11. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Downregulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006b;5:483-93.
12. Buchler P, Gazdhar A, Schubert M, Giese N, Reber HA, Hines OJ, Giese T, Ceyhan GO, Muller M, Buchler MW, Friess H. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 2005;242:791-800.
13. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K. Over-expression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-24.
14. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest. 1998;101:344-52.
15. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte WI, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126-30.
16. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005;41:2213-36.
17. Li Y, Bhuiyan M, Vaitkevicius VK, Sarkar FH. Molecular analysis of the p53 gene in pancreatic adeno-carcinoma. Diagn Mol Pathol. 1998;7:4-9.
18. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg. 2003;186:279-86.
19. Talar WR, Malecka PE. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit. 2006;12;RA186-RA193.
20. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg. 2004;198:591-9.
21. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-6.
22. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 2003;105:735-46.
23. Thayer SP, Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851-6.
24. Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 2006;66:7041-9.
25. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell. 2003;11:507-17.
26. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimeriza-tion in development and cancer. EMBO J. 2000;19:3159-67.
27. rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A. 1994;91:8132-6.
28. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-37.
29. Ullrich A, Coussens L, Hayfick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Sch-lessinger J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplifed gene in A431 epidermoid carcinoma cells. Nature. 1984;309:418-25.
30. Slieker LJ, Martensen TM, Lane MD. Synthesis of epidermal growth factor receptor in human A431 cells. Glycosylation-dependent acquisition of ligand binding activity occurs post-translationally in the endoplasmic reticulum. J Biol Chem. 1986;261:15233-41.
31. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110:763-73.
32. Ogiso, H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002;110;775-87.
33. Kil SJ, Carlin C. EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments. J Cell Physiol. 2000;185:47-60.
34. He C, Hobert M, Friend L, Carlin C. The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core. J Biol Chem. 2002;277:38284-93.
35. Castagnino P, Biesova Z, Wong WT, Fazioli F, Gill GN. Direct binding of eps8 to the juxtamembrane domain of EGFR is phosphotyrosine- and SH2-independent. Oncogene. 1995;10:723-9.
36. Martin NJ, Villalobo A. The human epidermal growth factor receptor contains a juxtamembrane cal-modulin-binding site. Biochemistry. 1998;37;227-36.
37. Li H, Villalobo A. Evidence for the direct interaction between calmodulin and the human epidermal growth factor receptor. Biochem J. 2002;362:499-505.
38. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfeld MD. Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences. Nature. 1984;307:521-7.
39. Ellis C, Moran M, Cormick MF, Pawson T. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature. 1990;343:377-81.
40. Countaway JL, Quilkin P, Girones N, Davis RJ. Multisite phosphorylation of the epidermal growth factor receptor. J Biol Chem. 1990;265:3407-16.
41. Heisermann GJ, Wiley HS, Walsh BJ, Ingraham HA, Fiol CJ, Gill GN. Mutational removal of the thr669 and ser671 phosphorylation sites alters substrate specifcity and ligand-induced internalization of the epidermal growth factor receptor. J Biol Chem. 1990;265;12820-7.
42. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science. 1990;247:962-4.
43. Normanno N, Bianco C, Luca A, Maiello MR, Salomon DS. Target based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003;10;1-21.
44. Harari D. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene. 1999;18:2681-9.
45. Roepstorff K, Grovdal L, Grandal M, Lerdrup M. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008;129:563-78.
46. Gray A, Dull TJ, Ullrich A. Nucleotide sequence of epidermal growth factor cDNA predicts at 128,000-molecular weight protein precursor. Nature. 1983;303:722-5.
47. Scott J, Urdea M, Quiroga M, Sanchez PR, Fong N, Selby M, Rutter WJ, Bell GI. Structure of a mouse submaxillary messenger RNA encoding epidermal growth factor and seven related proteins. Science. 1983;221:236-40.
48. Russell DW, Schneider WJ, Yamamoto T, Luskey KL, Brown MS, Goldstein JL. Domain of the LDL receptor: sequence homology with the epidermal growth factor precursor. Cell. 1984;37:577-85.
49. Hommel U, Dudgeon TJ, Fallon A, Edwards RM, Campbell IA. Structure-function relationships in human epidermal growth factor studied by site-directed mutagenesis and 1H NMR. Biochemistry. 1991;30:8891-8.
50. Olsen PS, Poulsen SS, Kirkegaard P, Nexo P. The role of submandibular saliva and epidermal growth factor in gastric cytoprotection. Gastroenterology. 1984;87:103-8.
51. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol. 1991;163:111-6.
52. Paulsen SS, Skov OP, Hess J, Kirkegaard P. Immunohistochemical localisation of epidermal growth factor in rat and man. Histochemistry. 1986;85:389-94.
53. Oka Y, Orth DN. Human plasma epidermal growth factor/p urogastrone is associated with blood platelets. J Clin Invest. 1983;72:249-59.
54. Ross R, Raines EW, Bowen DF. The biology of platelet-derived growth factor. Cell. 1986;46:155-69.
55. Fowler JE, Lau JLT, Ghash L, Mills SE, Mounzer A. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol. 1988;139:857-61.
56. Sugiyama K, Yonemura Y, Miyazaki I. Immunohistochemical study of epidermal growth factor and epidermal growth factor receptor in gastric carcinoma. Cancer. 1989;63:1557-61.
57. Bauknecht T, Kohler M, Janz I, Pfeiderer A. The occurrence of epidermal growth factor receptors and the characterisation of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. J Cancer Res Clin Oncol. 1989;115:193-9.
58. Derynck R. Transforming growth factor-α. Cell. 1988;54:593-5.
59. Marquardt H, Hunkapiller MW, Hood LE, Todaro GJ. Rat transforming growth factor type I: structure and relation to epidermal growth factor. Science. 1984;223:1079-82.
60. Lee DC, Rose TM, Webb NR, Todaro GJ. Cloning and sequence analysis of a cDNA for rat transforming growth factor-alpha. Nature. 1985;313:489-91.
61. Teixido J, Massague JM. Structural properties of a soluble bioactive precursor for transforming growth factor-alpha. J Biol Chem. 1988;263:3924-9.
62. Brachmann R, Lindquist PB, Nagashima N, Kohr W, Lipari T, Napier M, Derynck R. Transmembrane TGF- precursors activate EGF/TGF- α receptors. Cells. 1989;56:691-700.
63. Wong ST, Winchell LF, Cune BK, Earp HS, Teixido J, Massague J, Herman B, Lee DC. The TGF-alpha precursor expressed on the cell surface binds to the EGF receptor on adjacent cells leading to signal transduction. Cell. 1989;56:495-506.
64. Samsoondar J, Kobrin MS, Kudlow JE. Alpha transforming growth factor secreted by untransformed bovine anterior pituitary cells in culture. Int J Biol Chem. 1986;261:14408-13.
65. Coffey RJ, Derynck R, Wilcox JN, Bringman TS, Goustin AS, Moses HL, Pittelkow MR. Production and autoinduction of transforming growth factor-alpha in human keratinocytes. Nature. 1987;328:817-20.
66. Kommoss F, Wintzer HO, Kleist S, Kohler M, Walker R, Langton B, Tran VK, Pfeiderer A, Bauknecht T. In situ distribution of transforming growth factor alpha in normal human tissues and in malignant tumours of the ovary. J Pathol. 1990;162:223-30.
67. Wilcox JN, Derynck R. Localisation of cells synthesising transforming growth factor-alpha mRNA in the mouse brain. J Neurosci. 1988;8:1901-4.
68. Madtes DK, Raines EW, Sakariassen KS, Assoian RK, Sporn MB, Bell GI, Ross R. Induction of transforming growth factor-alpha in activated human alveolar macrophages. Cell. 1988;53:285-93.
69. Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR, Todaro GJ. Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science. 1987;235;350-2.
70. Nickell KA, Halper J, Moses HL. Transforming growth factors in solid human malignant neoplasms. Cancer Res. 1983;43:1966-71.
71. Salomon DS, Perroteau I, Kidwell WR, Turn J, Derynck R. Loss of growth responsiveness to epidermal growth factor and enhanced production of α-transforming growth factors in ras transformed mouse mammary epithelial cells. J Cell Physiol. 1987;130:397-409.
72. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, protransforming growth factor-α and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res. 1990;50:3934-9.
73. Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T, Shizume K. Insulin-like growth factor I and transforming growth factor-α as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. 1990;50:103-7.
74. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ, Ellingsworth L, Derynck R, Voorhees JJ. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science. 1989;243:811-3.
75. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mel Cell Biol. 1990;10:1969-81.
76. Shoyab M, McDonald VL, Bradley JF, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA. 1988;85:6528-32.
77. Johnson GR, Saeki T, Auersberg N, Gordon AW, Shoyab M, Salomon DS, Stromberg K. Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithehal cells: nuclear localisation of endogenous amphiregulin. Biochem Biophys Res Commun. 1991;180:481-8.
78. Todaro GJ, Rose TM, Spooner CE, Shoyab M, Plowman GD. Cellular and viral ligands that interact with the EGF receptor. Semin Cancer Biol. 1990;1:257-63.
79. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like ceils that is related to EGF. Science. 1991;251:936-9.
80. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA. Over-expression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987;51:1063-70.
81. Shankar V, Ciardiello F, Kim N, Derynck R, Liscia DS, Merlo G, Langton BC, Sheer D, Callahan R, Bassin RH, Lippman ME, Hynes N, Salomon DS. Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor-α cDNA. Mol Carcinog. 1989;2:1-11.
82. DiMarco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, Di Fiore PP. Autocrine interaction between TGF-α and the EGF receptor: quantitative requirements for induction of the malignant phenotype. Oncogene. 1989;4:831-8.
83. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9-15.
84. Ciardielloa F, Giampaolo T. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could infuence the response to anti-EGFR drugs. Eur J Cancer. 2003;39:1348-54.
85. Robertson KW, Reeves JR, Lannigan AK, Going JJ, Cooke TG, Stanton PD. Radioimmunohistoche-mistry of epidermal growth factor receptor in breast cancer. Arch Pathol Lab Med. 2002;126:177-81.
86. Albanell J, Rojo F, Averbuch S. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-24.
87. Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004;23:2057-70.
88. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31-53.
89. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:3-8.
90. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203-12.
91. Saito T, Okada S, Ohshima K, Yamada E, Sato M, Uehara Y, Shimizu H, Pessin JE, Mori M. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacel-lulin and EGF. Endocrinology. 2004; 145:4232-43.
92. Bachelot C, Rameh L, Parsons T, Cantley LC. Association of phosphatidylinositol 3-kinase, via the SH2 domains of p85, with focal adhesion kinase in polyoma middle t-transformed fbroblasts. Biochim Biophys Acta. 1996;1311:45-52.
93. Chattopadhyay A, Vecchi M, Ji Q, Mernaugh R, Carpenter G. The role of individual SH2 domains in mediating association of phospholipase C-g1 with the activated EGF receptor. J Biol Chem. 1999;274:26091-7.
94. Torrisi MR. Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. Mol Biol Cell. 1999;10:417-34.
95. Levkowitz G. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12:3663-74.
96. French AR, Tadaki DK, Niyogi SK, Lauffenburger DA. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem. 1995;270:4334-40.
97. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem. 1998;273:13819-27.
98. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31:637-43.
99. Carpenter G, Cohen S. Epidermal growth factor. Ann Rev Biochem. 1979;48:193-216.
100. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 1991;9:553-62.
101. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in patients with breast cancer. Breast Cancer Res Treat. 2002;1029:67-75.
102. Aziz SA, Pervez S, Khan S, Kayani N, Rahbar MH. Epidermal growth factor receptor (EGFR) as a prognostic marker: an immunohistochemical study on 315 consecutive breast carcinoma patients. J Pak Med Assoc. 2002;52:104-10.
103. Dancer J, Takei H, Ro JY, Lowery NM. Coexpression of EGFR and HER-2 in pancreatic ductal adeno-carcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fuorescencent in situ hybridization. Oncol Rep. 2007;18:151-5.
104. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg. 2006;23:74-9.
105. Thybusch BA, Beckmann S, Juhl H. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favorable tumor stage. Int J Surg Invest. 2001;2: 393-400.
106. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002;29:31-7.
107. Batzer AG, Rotin D, Urena JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol. 1994;14:5192-201.
108. Waters SB, Chen D, Kao AW, Okada S, Holt KH, Pessin JE. Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of Ras activation. J Biol Chem. 1996;271:18224-30.
109. Marais R, Marshall CJ. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 1996;27:101-25.
110. Johnson GR, Saeki T, Auersberg N, Gordon AW, Shoyab M, Salomon DS, Stromberg K. Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithehal cells: nuclear localisation of endogenous amphiregulin. Biochem Biophys Res Commun. 1991;80:481-8.
111. Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 2000;19:5429-39.
112. Lin H, Chen C, Li X, Chen BD. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res. 2002;272:192-8.
113. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002;4:556-64.
114. Stover DR, Becker M, Liebetanz J, Lydon NB. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85-α. J Biol Chem. 1995;270: 15591-7.
115. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88: 435-7.
116. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res. 2001;264: 29-41.
117. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006;18:77-82.
118. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59-71.
119. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS. Akt promotes cell survival by phosphoryla-ting and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-68.
120. Patterson RL, Rossum DB, Nikolaidis N, Gill DL, Snyder SH. Phospholipase C-g: diverse roles in receptor mediated calcium signaling. Trends Biochem Sci. 2005;30:688-97.
121. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol. 1998;18:790-8.
122. Wells A, Ware MF, Allen FD, Lauffenburger DA. Shaping up for shipping out: PLCgamma signaling of morphology changes in EGF stimulated fbroblast migration. Cell Motil Cytoskelet. 1999;44: 227-33.
123. Andl CD, Mzushima T, Oyama K, Bowser M, Nakagawa H, Rustgi, AK. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am. J Physiol Gastrointest Liver Physiol. 2004;287:1227-37.
124. Leaman DW, Pisharody S, Flickinger TW, Commane MA, Schlessinger J, Kerr IM, Levy DE, Stark GR. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol Cell Biol. 1996;16:369-75.
125. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem. 2003;278:1671-9.
126. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, Deurs B, Poulsen HS. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis. 2007;28:1408-17.
127. Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell. 2003;3:519-23.
128. Sugawa N, Ekstrand A, James C, Collins V. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplifed rearranged genes in human glioblastomas. Proc Natl Acad Sci USA. 1990;87:8602-6.
129. Omidfar K, Moinfar Z, Sohi AN, Tavangar SM, Haghpanah W, Heshmat R, Kashanian S, Larijani B. Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest. 2009;38:165-80.
130. Azuma M, Danenberg KD, Iqbal S, Khoueiry AE, Danenberg PV, Fazzone W, Ladner RD, Lenz H. EGFR and EGFR VIII gene expression in metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium 2006.
131. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 2000;60:3081-7.
132. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001;8:83-96.
133. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem. 1998;273:2817-22.
134. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284:31-53.
135. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta. 2005; 1756:127-44.
136. Eunice LK, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PH, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006;12:4283-7.
137. Normanno N, Bianco C, Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003;10:1-21.
138. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer. 2000;89:484-7.
139. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 1990;50:7077-80.
140. Grandis JR, Melhem MF, Gooding WE. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:799-801.
141. Lenferink AE, Pinkas KR, Poll ML. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998;17:3385-97.
142. Karunagaran D, Tzahar E, Beerli RR. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996;15:254-64.
143. Prenzel N, Zwick E, Leserer M, Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversifcation. Breast Cancer Res. 2000;2:184-90.
144. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene. 2001;20:1594-1600.
145. Bates SE, Davidson NE, Valverius EM. Expression of transforming growth factor-α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional signif-cance. Mol Endocrinol. 1988;2:543-55.
146. Lombardo CR, Consler TG, Kassel DB. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by csrc: identifcation of phosphorylation sites and c-src SH2 domain binding sites. Biochemistry. 1995;34:16456-66.
147. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999;274:8335-43.
148. Boerner JL, Demory Ml, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol. 2004;24:7059-71.
149. Yamauchi T. Tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem. 2000;275:33937-44.
150. 125I-Labeled human epidermal growth factor: binding, internalization, and degradatioin in human fbroblasts. J Cell Biol. 1976;71:159-71.
151. Schmid SL. The mechanism of receptor-mediated endocytosis: more questions than answers. BioEs-says. 1992;14:589-96.
152. Reguinot I, Liall RM, Willingham MC, Pastan I. Downregulation of the epidermal growth factor receptor in KB cell is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci USA. 1984;81:2384-8.
153. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12:541-52.
154. Seger R, Krebs EG. The MAP kinase signaling cascade. FASEB J. 1995;9:726-35.
155. Wang Q, Villeneuve G, Wang G. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep. 2005;6:942-8.
156. Wiley HS, Cunningham DD. The endocytotic rate constant: a cellular parameter for quantitating receptor-mediated endocytosis. J Biol Chem. 1982;257:4222-9.
157. Gorden P, Carpentier JL, Cohen S, Orci I. Epidermal growth factor: morphological demonstration of binding, internalization and lysosomal association in human fbroblast. Proc Natl Acad Sci USA. 1978;75:5025-9.
158. Haigler HT, McKanna JA, Cohen S. Direct visualisation of the binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431. J Cell Biol. 1979;81:382-95.
159. Kornfeld S, Mellman I. The biogenesis of lysosomes. Ann Rev Cell Biol. 1989;5:482-525.
160. Lai WH, Cameron PH, Wada I, Doherty JJ, Kay DG, Posner RI, Bergeron JJM. Ligand-mediated internalization, recycling, and downregulation of the epidermal growth factor receptor in vivo. J Cell Biol. 1989;109:2741-9.
161. Smythe E, Warren G. The mechanism of receptor-mediated endocytosis. Eur J Biochem. 1991;202: 689-99.
162. Griffths G. In: Endocytosis; Courtoy PJ, Springer; Ed; Verlag: Berlin, Heidelberg; 1992. p.73-83.
163. Carpentier JL, White MF, Orci L, Kahn RC. Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells. J. Cell Biol. 1987;105:2751-62.
164. Gur G, Zwang Y, Yarden Y. In: Endosomes, Ivan Dikic, Ed; Landes Bioscience and Springer Science+Business Media: Israel; 2006. p.101-118.
165. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. Differential regulation of EGF receptor internali-zation and degradation by multiubiquitination within the kinase domain. Mol Cell. 2006;21:737-48.
166. Barriere H, Nemes C, Du K, Lukacs GL. Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endosomal sorting machinery. Mol Biol Cell. 2007;18:3952-65.
167. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029-40.
168. Jiang X, Sorkin A. Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING fnger and proline-rich domains but not receptor polyubiquitylation. Traffc. 2003;4:529-43.
169. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden YA. Mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 2002;21:303-13.
170. Grovdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 2004;300:388-95.
171. Huang F, Sorkin A. Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and suffcient to support receptor endocytosis. Mol Biol Cell. 2005;16:1268-81.
172. Williams RL, Urbe S. The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol. 2007;8:355-68.
173. Huang F, Goh LK, Sorkin A. EGF receptor ubiquitination is not necessary for its internalization. Proc Natl Acad Sci USA. 2007;104:16904-9.
174. Raiborg C, Stenmark H. Hrs and endocytic sorting of ubiquitinated membrane proteins. Cell Struct Funct. 2002;27:403-8.
175. Polo S, Sigismund S, Faretta M, Guidi M, Capua MR, Bossi G, Chen H, De Camilli P, Di Fiore PP. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature. 2002;416:451-5.
176. Hirano S, Kawasaki M, Ura H, Kato R, Raiborg C, Stenmark H, Wakatsuki S. Double-sided ubiquitin binding of Hrs-UIM in endosomal protein sorting. Nat Struct Mol Biol. 2006:13:272-7.
177. Orth JD, Krueger EW, Weller SG, McNiven MA. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res. 2006;66:3603-10.
178. Sigismund S, Woelk T, Puri C. Clathrin independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA. 2005;102:2760-5.
179. Kazazic M, Roepstor VK, Johannessen LE, Pedersen NM, Deurs B, Stang E, Madshus IH. EGF-induced activation of the EGF receptor does not trigger mobilization of caveolae. Traffc. 2006;7:1518-27.
180. Wiley HS, Herbst JJ, Walsh BJ, Lauffenburger DA, Rosenfeld MG, Gill CN. The role of tyrosine kinase activity in endocytosis, compartmentalization, and down-regulation of the epidermal growth factor receptor. J Biol Chem. 1991;266:11083-94.
181. Ware MF, Tice DA, Parsons SJ, Lauffenburger DA. Overexpression of cellular Src in fbroblasts enhances endocytic internalization of epidermal growth factor receptor. J Biol Chem. 1997;272:30185-90.
182. Lazar CS, Cresson CM, Lauffenburger DA, Gill GN. The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface, Mol Biol Cell. 2004;15:5470-80.
183. Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar-Sagi D. hSpry2 is targeted to the ubiquitin-depen-dent proteasome pathway by c-Cbl. Curr Biol. 2003;13:308-14.
184. Burke PM, Wiley HS. Human mammary epithelial cells rapidly exchange empty EGFR between surface and intracellular pools. J Cell Physiol. 1999;180:448-60.
185. Wiley HS, Herbst JJ, Walsh BJ, Lauffenburger DA, Rosenfeld MG, Gill GN. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem. 1991;266:11083-94.
186. Decker SJ. Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun. 1990;166:615-21.
187. Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-α: differential intracel-lular routing and processing of ligand-receptor complexes. Cell Regul. 1991;2:599-612.
188. Burzykowski T, Buyse M, Piccart GMJ. Evaluation of tumor response, disease control, progression free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-92.
189. Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
190. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isofavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005;65:6934-42.
191. Lian JP, Word B, Taylor S, Hammons GJ, Lyn-Cook BD. Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res. 2004;24:133-7.
192. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 2004;101:2351-62.
193. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006;66:2500-5.
194. Ding XZ, Adrian TE. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas. 2002;25:e71-76.
195. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25:2607-15.
196. Hochster HS. Newer approaches to gemcitabine-based therapy of pancreatic cancer: fxed-dose-rate infusion and novel agents. Int J Radiat Oncol Biol Phy. 2003;56:24-30.
197. Macmillan Cancer Support. http://www.macmillan.org.uk/Cancertype/Pancreas/Treatment/Chemothe-rapy.html (Accessed March15, 2010).
198. Fisher BJ, Perera FE, Kocha W, Tomiak A, Taylor M, Vincent M. Analysis of the clinical beneft of 5-fuorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 1999;45:291-5.
199. Sun D, Urrabaz R, Buzello C, Nguyen M. Effects of cisplatin on expression of DNA ligases in MIA PaCa human pancreatic cancer cells. Biochem Biophys Res Commun. 2002;298:537-44.
200. Klapdor R, Svendsen JM, Seutter R. Combination therapy with oxaliplatin + gemcitabine in advanced pancreatic cancer. Eur J Cancer. 1999;35:S146.
201. Bosch X. Fluorouracil and mitomycin for pancreatic cancer. Lancet Oncol. 2005;6: 644.
202. Palmer KR, Kerr M, Knowles G. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Brit J Surg. 1994;81:882-5.
203. Fung, MC, Ishiguro H, Takayama S. Survival beneft of chemotherapy treatment in advanced pancreatic cancer. Proc Am Soc Oncol. 2003;22:288.
204. Ishii H, Furuse J, Nagase M, Yoshino M. Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J Gastroenterol Hepatol. 2009;20:62-6.
205. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997;15:331-41.
206. Tempero M, Plunkett W, Ruiz VHV, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fxed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-8.
207. Louvet C, Labianca R, Hammel P. Gemcitabine in combination with oxaliplatin compared with gem-citabine alone in advanced pancreatic cancer. J Clin Oncol. 2005;23:3509-16.
208. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
209. Reni M, Cordio S, Milandri, C. Gemcitabine versus cisplatin, epirubicin, fuorouracil and gemcitabine in advanced pancreatic cancer: a randomized controlled multicenter phase III trial. Lancet Oncol. 2005;6:369-76.
210. Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY. Phase II study of 5-fuorouracil and pacli-taxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:529-33.
211. Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Farnaz R, Milanesi E, Bertetto O, Ciuf-freda L. Oxaliplatin, 5-fuorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol. 2009;32:44-8.
212. Klinkenbijl JHG, Sahmoud T, Pel R. Radiotherapy and 5FU after curative resection for cancer of the pancreas and periampullar region: a phase III trial of the EORTC and GITCCG. Eur J Cancer. 1997;33:1239.
213. Ghaneh P, Neoptolemos JP. Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Surg Oncol Clin N Am. 2004;13:567-87.
214. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol. 2008 May;26(15):S4506.
215. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette CO. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Defnitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592-9.
216. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcita-bine chemotherapy before and after fuorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-26.
217. Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical beneft with gemcitabine as frst line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
218. Berlin J, Catalano P, Thomas J, Kluger J, Haller DG, Nenson AB. A phase III study of gemcitabine in combination with 5FU versus gemcitabine alone in patients with advanced pancreatic carcinoma: an Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol. 2001;20:127a.
219. Cascinu S, Silva R, Barni S. A combination of gemcitabine and 5FU in advanced pancreatic cancer, a report from the Italian Group of Digestive Tract Cancer (GISCAD). Br J Cancer. 1999;80:1595-8.
220. Louvet C, Andre T, Lledo G. Gemcitabine-Oxaliplatin (GEMOX regimen) in advanced pancreatic carcinoma (APC). A Gercor multicenter phase II study. Proc Am Soc Clin Oncol. 2001;20:127a.
221. Shepard RC, Levy D, Stuart K. Pancreatic cancer: biweekly gemcitabine/docetaxel chemotherapy. Proc Am Soc Clin Oncol. 2001;20:154a.
222. Lutz M P, Ducreux M, Wagener T. Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proc Am Soc Clin Oncol. 2002;21:125a.
223. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E. Randomized study of gemcitabine and oxaliplatin versus gemcitabine (fxed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group, J Clin Oncol. 2009;27:3778-85.
224. Colucci G, Labianca R, Costanzo FD, Gebbia V, Carteni G, Massidda B, Dapretto E. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as frst-line treatment of patients with advanced pancreatic cancer: The GIP-1 Study, J Clin Oncol. 2010;28:1645-51.
225. Chabot JA, Tsai WA, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clini Oncol. 2010;28:2058-63.
226. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fxed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009;27:5506-12.
227. Choi JH, Oh SY, Kwon HC, Kim JH, Lee JH, Lee S, Lee DM, Kim SH. Gemcitabine versus gemcita-bine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis. Cancer Res Treat. 2008;40:22-6.
228. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A. Recombinant antibody toxins specifc for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer. 2000;86:269-75.
229. Ciardiello F, Caputo R, Troiani T, Bordello G, Kandimalla ER, Agrawal S. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer. 2001;15:172-8.
230. Magne N, Castadot P, Ghalibafan M, Soria JC, HaieMeder C, Bourhis J, Deutsch E. The effcacy and toxicity of EGFR in the settings of radiotherapy: focus on published clinical trials. Eur J Cancer. 2008;44:2133-43.
231. Baselga J, Pfster D, Cooper MR, Cohen R, Burtness B, Bos M. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904-14.
232. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther. 2001;1:719-32.
233. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antian-giogenic mechanisms. Clin Cancer Res. 2000;6:1936-48.
234. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological effcacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-8.
235. Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. EGF receptor antibody downregulates mutant receptors and inhibits tumors expressing EGFR mutations. J. Biol Chem. 2006;281:40183-92.
236. Baselga J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin Oncol. 2000;18:904-14.
237. Folprecht G. Cetuximab and irinotecan/5-fuorouracil/folinic acid is a safe combination for the frst-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006;17:450-6.
238. Philip PA, Benedetti J, Fenoglio-Preiser C. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma SWOG S0205 study. J Clin Oncol. 2007;25:LBA4509.
239. Cascinu S, Berardi R, Labianca R. Cetuximab plus gemcitabine and cisplatin compared with gemcita-bine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008;9:39-44.
240. Kullmann F, Hollerbach S, Dollinger M. In: 2007 gastrointestinal cancers symposium. Cetuximab plus gemcitabine/oxaliplatin in frst line metastatic pancreatic cancer. First results from a multicenter phase II study; 2007.
241. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22:2610-6.
242. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angioge-nesis. Clin Cancer Res. 2000;6:2166-74.
243. Krempien R, Munter MW, Timke C, Friess H, Hartung G, Herfarth KK. Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial. 2007 ASCO annual meeting proceedings. J Clin Oncol. 2007;25:4573.
244. Abraham J. Panitumumab in metastatic colorectal cancer. Commun Oncol. 2007;4:121-6.
245. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
246. Yang XD, Jia XC, Corvalan J, Wang P, Wu E, Zhang L. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment. Proc Am Soc Clin Oncol. 2000; 19 [abstract 183].
247. Yang XD, Jia XC, Corvalan JRF, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer Res. 1999;59:1236-43.
248. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther. 2009;8:1536.
249. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer. 2006;94:1293-9.
250. Strumberg D, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F. In: 2006 ASCO annual meeting proceedings. Safety, effcacy and pharmacokinetics of nimotuzumab,a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). J Clin Oncol. 2006;24:12504.
251. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. 2000;59:753-67.
252. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Effcacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885-92.
253. Solomon B, Hagekyriakou J, Trivett MK, Stacker SS, McArthur GA, Cullinane C. EGFR blockade with ZD1839 (Iressa) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;55:713-23.
254. Shadad F, Matin K, Evans T, Volkin RL, Kiefer GJ, Schlesselman JJ. Phase II study of geftinib and docetaxel as salvage therapy in patients (pts) with advanced pancreatic adenocarcinoma (APC). 2006 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24:4120.
255. Fountzilas G, Murray S, Xiros N, Karayannopoulou G, Dafni U, Linardou H. Gemcitabine (G) combined with geftinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial.ASCO annual meeting proceedings. Part I. J Clin Oncol. 2007;25:15016.
256. Brell JM, Matin K, Evans T, Volkin RL, Keifer GJ, Schlesselman JJ. Phase II study of geftinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after frst-line therapy. Final results. 2007 ASCO annual meeting proceedings. Part I. J Clin Oncol. 2007;25:4586.
257. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor geftinib (ZD1839). Clin Cancer Res. 2004;10:6476-86.
258. Xu JM, Azzariti A, Severino M, Lu B, Colucci G, Paradiso A. Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin. Biochem Pharmacol. 2003;66:551-63.
259. Iwata K, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proceedings of American Society; Clin Oncol; 2002.
260. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan, DE, Moyer JD. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999;291:739-48.
261. Pollack A. Market place; Panel Backs One Drug, But Not 2nd.; New York Times: New York, 2005.
262. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006;107:1207-18.
263. Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother. 2006;7:177-93.
264. Burris HA. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol. 2005;32:S1-3.
265. Blaszkowsky LS, Kulke KH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX. In: 2005 ASCO Annual Meeting Proceedings, Part I. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. J Clin Oncol. 2005;23:4099.
266. Moore MJ, Goldstein D, Hamm J. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trail of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
267. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erloti-nib (Tarceva). Cancer Res. 2005;65:3328-35.
268. Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol. 2005;28:570-5.
269. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
270. Huang XL, Pawliczak R, Cowan MJ, Gladwin MT, Madara P, Logun C. Epidermal growth factor induces p11 gene and protein expression and down-regulates calcium ionophore-induced arachidonic acid release in human epithelial cells. J Biol Chem. 2002;277:38431-40.
271. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM. Radiosensiti-zation by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res. 2004;10:691-700.
272. Zinner RG, Donato NJ, Nemunaitis JJ, Cunningham CC, Shin HJ, Zentgraf RE. Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033. Proceedings of American Society; Clin Oncol; 2002.
273. Gupta S, Pal A, Vyas SP. Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin Drug Deliv. 2010;7:371-402.
274. Drabu S, Khatri S, Babu S, Verma D. Nanotechnology: an introduction to future drug delivery system. J Chem Pharm Res. 2010;2:171-9.
275. Arruebo M, Fernandez-Pacheco R, Ibarra MR, Santamaria M. Magnetic nanoparticles for drug delivery. Nanotoday. 2007;2:22-32.
276. Huwyler J, Drewe J, Krahenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nano-med. 2008;3:21-9.
277. Moghimi SM, Patel HM. Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. Biochim Biophys Acta. 1992;1135:269-74.
278. Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, Unger C, Hopt UT, Schaechtele C, von Dobschuetz E, Massing U. Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas. 2009;38:330-7.
279. Pal A, Khan S, Wang YF, Kamath N, Sarkar AK, Ahmad A, Sheikh S, Ali S, Carbonaro D, Zhang A, Ahmad I. Preclinical safety, pharmacokinetics and antitumor effcacy profle of liposome-entrapped SN-38 formulation. Anticancer Res. 2005;25:331-41.
280. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31.
281. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 2009;29:1895-9.
282. Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep. 2006;15:1201-4.
283. Kalra AV, Campbell RB. Development of 5-FU and doxorubicin loaded cationic liposomes against human pancreatic cancer: implication for tumor vascular targeting. Pharmaceut Res. 2006;23:2809-17.
284. Cosco D, Bulotta A, Ventura M, Celia C, Calimeri T, Perri G, Paolino D, Costa N, Neri P. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol. 2009;64:1009-20.
285. Sun M, Wang Y, Shen J, Xiao Y, Su Z, Ping Q. Octreotide-modifcation enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology. 2010;21:475101.
286. Harrington KJ. Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Invest Drugs. 2001;10:1045-61.
287. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol. 1999;17:697-705.
288. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, Korn R, Desai N, Iglesias J, Hidalgo M. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study. J Clin Oncol. 2009;27:4525.
289. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated cur-cumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol. 2007;5:3.
290. Trickler WJ, Khurana J, Nagvekar AA, Dash AK. Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment. AAPS PharmS-ciTech. 2010;11:392-401.
291. Vandana M, Sahoo SK. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials. 2010;31:9340-56.
292. Gang J, Park SB, Hyung, W, Choi EH, Wen J, Kim HS, Shul YG, Haam S, Song SY. Magnetic poly ε-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target. 2007;15:445-53.
293. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-27.
294. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res.1998;58:2825-31.
295. Mc Laughlin P, Grillo-Lopez AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-33.
296. Aggarwal S, Yadav S, Gupta S. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed Nanotechnol. 2011;7:137-8.
297. Lutz MP. Pancreatic cancer: liposomal paclitaxel added to gemcitabine extends survival in unresecta-ble disease. Oncol Times. 2009;31:8-9.
298. Lim SK, Park HJ, Choi EK, Kim JS. Long-circulating, temperature-sensitive and EGFR-targeted lipo-somes for drugs delivery. Key Eng Mat. 2007;342-343:537-40.
299. Magadal P, Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008;10:565-76.
300. Saula JM, Annapragadac AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Controlled Release. 2006;114:277-87.
301. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 2009;5:235-43.
302. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Mukherjee P. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008;68:1970-8.
303. Baker M. Upping the ante on antibodies. Nat Biotechnol. 2005;23:1065-72.
304. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23:1073-8.
305. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Discov. 2004;3:711-5.
306. Butowski N, Chang SM. Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control. 2005;12:116-24.
307. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296-313.
308. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343-57.
309. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004;64:5355-62.
310. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the effcacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005;24:487-99.
311. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet. 2003;362:62-4.
312. Buter J, Giaccone G. Medical treatment of non-small-cell lung cancer. Ann Oncol. 2005;16: ii229-ii232.
313. Baselga J. The EGFR as a target for anticancer therapy--focus on cetuximabs. Eur J Cancer. 2001;37:S16-22.
314. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and geftinib. Lancet. 2003;361:137-9.